BridgeBio Pharma BBIO Tax on Share Settlement
Tax on Share Settlement at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's tax on share settlement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's tax on share settlement?
- BridgeBio Pharma (BBIO) reported tax on share settlement of $4.07M in Q1 2026.
- How has BridgeBio Pharma's tax on share settlement changed year-over-year?
- BridgeBio Pharma's tax on share settlement increased by 129.4% year-over-year, from $1.78M to $4.07M.
- What is the long-term trend for BridgeBio Pharma's tax on share settlement?
- Over 4 years (2021 to 2025), BridgeBio Pharma's tax on share settlement has grown at a 31.6% compound annual growth rate (CAGR), from $4.75M to $14.23M.
- What does tax on share settlement mean?
- Cash paid by the company to cover employee taxes on vested stock awards.
- How do you interpret tax on share settlement?
- Higher payments generally correlate with higher levels of employee equity compensation and vesting activity.
- How does tax on share settlement compare across companies?
- Standard across all companies with significant stock-based compensation plans.